Legal 500
Log in or register
  • Rankings

    • Jurisdictions
    • Submissions
    • Future Lawyers
  • Firms & Lawyers

    • Service Providers
    • Barristers’ Sets
    • Networks
    • Interview with…
  • In-House

    • In-House Content
    • GC Powerlist
  • Knowledge Centre

    • Data Products
    • Legal Business
    • Market Intelligence
    • About us

      • Legal 500
      • FAQs
      • Marketing
      • Careers
      • Trust Centre
      • Contact us
  • Comparative Guides
  • Events
  • Legal 500 TV

About us

  • Legal 500
  • FAQs
  • Marketing
  • Careers
  • Trust Centre
  • Contact us
  • Deutschland DE
  • Paris FR
  • Rankings

    • Jurisdictions
    • Submissions
    • Future Lawyers
  • Firms & Lawyers

    • Service Providers
    • Barristers’ Sets
    • Networks
    • Interview with…
  • In-House

    • In-House Content
    • GC Powerlist
  • Knowledge Centre

    • Data Products
    • Legal Business
    • Market Intelligence
    • About us

      • Legal 500
      • FAQs
      • Marketing
      • Careers
      • Trust Centre
      • Contact us
  • Comparative Guides
  • Events
  • Legal 500 TV

About us

  • Legal 500
  • FAQs
  • Marketing
  • Careers
  • Trust Centre
  • Contact us
  • Deutschland DE
  • Paris FR

© 2026 Legalease Ltd. All rights reserved

Registered company in England & Wales No. 02427356 VAT GB 321 5727 22

Registered address: 188 Fleet Street, London, EC4A 2AG

  • Legal 500 Trust Centre
  • Contact Us
  • home
  • Market Intelligence
  • Search

7,150 results found

Use advanced search filters to refine your search

2 filters applied

Advanced search filters

Topics
Countries
Contributor

Start typing to add contributors

Content type
Show options
  • Article

    Women's History Month Spotlight: Rosalyn Yalow

    Big Molecule Watch honors Women's History Month by recognizing the women who have contributed to the advancement of biologics and biosimilars.
    United StatesFood, Drugs, Healthcare, Life Sciences
    Goodwin Procter LLP
    Goodwin Procter LLP
  • Article

    Bipartisan House Bill Would Direct Secretary Of Commerce To Develop Prioritized Action Plan For Biomanufacturing

    Representatives Bob Latta and Debbie Dingell have introduced the BEDROCK Act, legislation aimed at strengthening American biomanufacturing competitiveness and reducing dependence on China. The bill would designate a Commerce Department official to lead efforts, assess supply-chain vulnerabilities, develop action plans, and streamline federal commercialization processes to help scale domestic production of biologically-manufactured products.
    United StatesGovernment, Public Sector
Bergeson & Campbell
Bergeson & Campbell
  • Article

    5 Costly IP Mistakes To Avoid

    Patents serve as the fundamental currency of the medical technology industry, enabling companies to raise capital, form strategic alliances, and generate licensing revenue. Yet many medtech innovators fail to treat their intellectual property as a core business asset, risking the loss of competitive advantage and market exclusivity that could diminish the full value of their innovations.
    United StatesIntellectual Property
    Greenberg Traurig
    Greenberg Traurig
  • Article

    Biolojic Design Ltd. Research Collaboration And License Agreement With Eli Lilly

    Pearl Cohen advises Biolojic Design Ltd. on intellectual property matters on the research collaboration and license agreement with Eli Lilly that will leverage Biolojic's AI-based
    United StatesIntellectual Property
    Pearl Cohen Zedek Latzer Baratz
    Pearl Cohen Zedek Latzer Baratz
  • Article

    Bristol-Myers Squibb And AstraZeneca Settle Anti-PD-L1 Antibody Product Litigation

    We previously reported on Bristol-Myers Squibb's ("BMS") complaint alleging AstraZeneca's PD-L1 antibody product, IMFINZI (durvalumab), infringed U.S. Patent No. 9,402,899
    United StatesIntellectual Property
    Goodwin Procter LLP
    Goodwin Procter LLP
  • Article

    CAFC Affirms No Interference-In-Fact In University Of California V. Broad Institute

    In University of California v. Broad Institute, Inc., No. 2017-1907 (Fed. Cir. Sept. 10, 2018), the CAFC affirmed the PTAB's holding that there was no interference-in-fact between a pending University
    United StatesIntellectual Property
    Finnegan, Henderson, Farabow, Garrett & Dunner LLP
    Finnegan, Henderson, Farabow, Garrett & Dunner LLP
  • Article

    Congress Takes Aim At Counterfeit Drugs

    Bills were introduced in both the House and the Senate earlier this month to increase the penalties for trafficking in counterfeit drugs.
    United StatesIntellectual Property
    Foley Hoag LLP
    Foley Hoag LLP
  • Article

    Freedom To Utilize Genetic Resources? The Nagoya Protocol Two Years Later

    Two years ago this month, the N agoya Protocol on Access to Genetic Resources and the Fair and Equitable Sharing of Benefits from their Utilization to the Convention on Biological Diversity ("Protocol") entered into international force.
    United StatesIntellectual Property
    WilmerHale
    WilmerHale
  • Article

    Inherent Written Description

    It has been well established that 35 U.S.C. § 112 contains both a written description requirement and an enablement requirement Ariad Pharmaceuticals, Inc. v. Eli Lilly and Co., 598 F.3d 1336, 1341.
    United StatesIntellectual Property
    Smith Gambrell & Russell
    Smith Gambrell & Russell
  • Article

    Join the Party! CAFC Hears IPR Appeal From Parties That Were Time-Barred From Filing Petition

    Research Corporation Technologies, Inc. sued Mylan Pharmaceuticals, Inc., Breckenridge Pharmaceutical, Inc., and Alembic Pharmaceuticals Ltd., in federal district court, accusing them...
    United StatesIntellectual Property
    Marshall, Gerstein & Borun LLP
    Marshall, Gerstein & Borun LLP
  • Article

    Konstantin Linnik Blogs For Massbiohq On Best Practices In Protecting And Exploiting Intellectual Property

    Konstantin Linnik, a partner in the firm’s Life Sciences practice group, published an article on MassBio’s blog MassBioHQ, titled "Whose Invention Is It Anyway?"
    United StatesIntellectual Property
    Nutter McClennen & Fish LLP
    Nutter McClennen & Fish LLP
  • Article

    "Navigating AI's Impact On Life Sciences And Patent Law"

    Marshall Gerstein Partner Noah Tilton contributed a column to Life Science Leader discussing artificial intelligence's impact on the life science industry. With all the benefits of this emerging technology – such as drug discovery, clinical trials, and regulatory compliance – also come challenges for protecting intellectual property.
    United StatesIntellectual Property
    Marshall, Gerstein & Borun LLP
    Marshall, Gerstein & Borun LLP
  • Article

    New Restrictions On Int'l Trade In Genetic Resources

    On Oct. 12, 2014, the Nagoya Protocol on Access to Genetic Resources and the Fair and Equitable Sharing of Benefits from their Utilization entered into international force.
    United StatesIntellectual Property
    WilmerHale
    WilmerHale
  • Article

    One Patent Law, Two Economic Sectors

    Claire Laporte has written a thoughtful article on whether a single patent system can satisfy the competing and perhaps inconsistent demands of life science and high-tech innovation.
    United StatesIntellectual Property
    Foley Hoag LLP
    Foley Hoag LLP
  • Article

    Patenting AI Discoveries In Life Sciences: Overcoming Eligibility, Disclosure, And Inventorship Challenges

    The pharmaceutical and biotechnology industries face transformative opportunities through artificial intelligence and machine learning integration.
    United StatesIntellectual Property
    Taft, Stettinius & Hollister LLP
    Taft, Stettinius & Hollister LLP
  • Article

    Podcast: Susan Tull On Patenting The Future Of Medicine

    Artificial intelligence, or AI, is rapidly transforming the world of medicine. AI computers are diagnosing medical conditions at a rate equal to or better than humans ...
    United StatesIntellectual Property
    Finnegan, Henderson, Farabow, Garrett & Dunner LLP
    Finnegan, Henderson, Farabow, Garrett & Dunner LLP
  • Article

    Preliminary Injunction Issued Against Samsung Bioepis In Aflibercept BPCIA Litigation

    In a sealed order that issued last week, the Court has granted a preliminary injunction against Samsung Bioepis in the aflibercept BPCIA litigation brought by Regeneron.
    United StatesIntellectual Property
    Goodwin Procter LLP
    Goodwin Procter LLP
  • Article

    Regeneron's Disclaimer Of Aflibercept Formulation Patent Causes PTAB Denial Of Institution Of Celltrion PGR

    In the decision denying institution, the PTAB stated that on March 14, 2022, Regeneron had notified the PTAB that it intended to disclaim the '231 patent.
    United StatesIntellectual Property
    Goodwin Procter LLP
    Goodwin Procter LLP
  • Article

    Regeneron Files BPCIA Complaint Against Sandoz Regarding Aflibercept Biosimilar

    On August 26, 2024, Regeneron filed a BPCIA complaint in the District Court for the District of New Jersey against Sandoz Inc. related to Sandoz's ENVEEZU (aflibercept-abzv).
    United StatesIntellectual Property
    Goodwin Procter LLP
    Goodwin Procter LLP
  • Article

    Single Antibody Disclosed In Specification Not Sufficient To Describe Densely Populated Genus

    In a decision that appears to conflict with the Court's own precedent, the U.S. Court of Appeals for the Federal Circuit recently tightened the written description requirement of 35 U.S.C. § 112, first paragraph, as it is applied to biotechnology inventions.
    United StatesIntellectual Property
    McDermott Will & Emery
    McDermott Will & Emery
  • Showing 581–600 of 7150 results

    PreviousNext
    Legal Intelligence Newsletters: sign up for the latest legal and regulatory news on your chosen topics